Trump Signs Executive Order for Kidney Care Reform

News Article

OR Today
June 20, 2019

Vascular Surgeon Presents Data on

216 Ellipsys EndoAVF System Procedures

News Article

The Journal of Vascular and Interventional Radiology (JVIR), March 26, 2019

JVIR, SIR Foundation Spotlight Treatments for

End-Stage Renal Disease and Diabetes

News Article

L’Echo Republican, February 14, 2019

A Minor Revolution for Dialysis Patients

News Article

U.S. Dept. of Veterans Affairs, February 6, 2019

 VA Performs Revolutionary Vascular Procedure

For Immediate Release

Business Wire, December 7, 2018

SKI Vascular Center is First Ambulatory Surgical Center in the Nation to Utilize FDA-Approved Ellipsys System for Non-Surgical Dialysis Fistula Creation

Local Interventional Nephrologists Randy Cooper, MD and Umar Waheed, MD, Pioneer Breakthrough Endovascular Arteriovenous Fistula (endoAVF^®) Technology for ESRD Patients

For Immediate Release

Washington, DC – November 15, 2018

Avenu Medical Unveils Ellipsys – a Non-Surgical Fistula Creation System – with Live Simulcast Procedure at CiDA

Avenu’s Endovascular Arteriovenous Fistula (endoAVF^®) Technology for ESRD Patients Receives Favorable Medicare Reimbursement Code while Exhibiting at Controversies in Dialysis Access Meeting

News Article

Business Wire, October 4, 2018

Richmond Vascular Center/Jeffrey Hull, M.D. First in Nation to Utilize FDA-approved Ellipsys System.

News Article

Nephrology News & Issues, September 2018

Technology helps put the AVF in a new light

For Immediate Release

San Juan Capistrano, CA, USA – June 26, 2018

Avenu Medical Receives FDA Approval for Ellipsys Vascular Access System for Non-Surgical Dialysis Fistula Creation Vascular Access System

Breakthrough Endovascular Arteriovenous Fistula (endoAVF^®) Technology Approved for Hemodialysis Access

Dr. Mallios demonstrates new endoAVF^® technology in Europe with the Ellipsys System.

Paris Channel 5 TV, Paris, France

September 2017

For Immediate Release

Avenu Medical Receives CE Mark Approval for the Ellipsys^® Vascular Access System

Company also completes full patient enrollment for pivotal Phase III clinical trial in the United States